SURVYR

TCRT

Alaunos Therapeutics, Inc.
$2.97
−$0.16 (5.11%)Oct 20 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-77%-46%-15%+15%+46%Oct 2025Oct 2026Apr 202652w high $4.5052w low $0.72
TCRTSPY
Wall St. Highest PT $5.53 (+86.2%) Wall St. Avg PT $4.53 (+52.5%)
$1$2$3$5$6POC $3Hi $6Avg $5
Underwater Drawdown %Max DD -83.0%Current -31.9%
0.0%-83.0%
Relative Strength vs SPY-19.4% vs SPYUnderperforming
+107%0%-107%
1W
−$0.06 (1.98%)
1M
+$1.77 (147.50%)
3M
+$0.88 (42.11%)
6M
+$0.19 (6.83%)
YTD
−$0.26 (8.05%)
1Y
−$0.11 (3.57%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for TCRT
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$8.7M
P/E (next 12 months, estimated)-5.0
52-week range$0.72 – $4.50
Dividend yieldNo dividend

What they do

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for TCRT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

TCRT earningsNo upcoming date on file
Last 4 quarters · EPS vs estimate
Apr 1, 2024-$17.09est -$4.50−279.9%Below estimates
Nov 14, 2023-$4.41est -$5.25+16.0%Above estimates
Aug 14, 2023-$6.00est -$6.75+11.1%Above estimates
May 10, 2023-$6.00est -$6.60+9.1%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 01:31:19 ET
22-0522-0822-1123-0323-0523-0823-1124-04-17.090.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$3.0K–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Top Premarket Gainers
MT Newswires · Oct 16
BC-Most Active Stocks
Associated Press · Oct 14
Another Paragon spinout goes public through reverse merger
BioPharma Dive · Oct 13
Top Midday Gainers
MT Newswires · Oct 13
Alaunos Therapeutics Completes Velaris Acquisition; Shares Surge
MT Newswires · Oct 13

Stats refreshed 2026-10-21 01:31:19 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026